TP53 wild-type

Phase 3 trial results presented at the #ASCOPlenarySeries show that selinexor has the potential to extend progression-free survival in patients with wild-type TP53 advanced or recurrent #EndometrialCancer. @ASCO @OBRtweets @GynCancerMD https://t.co/Dek5NNgoxY (@AaronTallent)

Selinexor maintenance generated an improvement in progression-free survival compared with placebo in patients with TP53 wild-type advanced or recurrent endometrial cancer who responded to first-line chemotherapy. @GynCancerMD @MountSinaiMiami #gyncsm https://t.co/2uFIB9qa1N (@OncLive)

Selinexor maintenance generated an improvement in progression-free survival compared with placebo in patients with TP53 wild-type advanced or recurrent endometrial cancer who responded to first-line chemotherapy. @GynCancerMD @MountSinaiMiami #gyncsm https://t.co/Yqx4ujHYxL (@OncLive)

A subgroup of patients with TP53 wild-type advanced/recurrent endometrial cancer experienced a long-lasting improvement in progression-free survival following treatment with maintenance selinexor vs placebo. #gyncsm | @GynCancerMD @ASCO https://t.co/MhThvOPnAr (@CancerNetwrk)

Maintenance Selinexor Shows Potential Improved PFS Signal in TP53 Wild-Type Endometrial Cancer https://t.co/09CnhGXXFi #gyncsm PFS of patients taking maintenance selinexor was 27.4 months compared with 5.2 months placebo. @GynCancerMD are studies planned in HGOC population? (@womenofteal)

🚨NEW!🚨#CancerResearch #ASCOPlenarySeries – A study from @GynCancerMD evaluates using maintenance therapy with #Selinexor to treat people with advanced or recurrent TP53 wild-type #EndometrialCancer https://t.co/PHsLLpuB1O #GyncSM #UterineCancer (@CancerDotNet)

Selinexor Maintenance After First-Line Chemotherapy Extends PFS in TP53 Wild-Type Advanced Endometrial Cancer @GynCancerMD @MountSinaiMiami @ASCO #gyncsm https://t.co/FIfHtAQZAx (@OncLive)

And TP53 wild type! #biliarytractcancer A new actionable target! (@cofiadeva)

July #ASCOPlenarySeries to ft. Long-term follow up of selinexor maintenance in pts w TP53wt adv. or recurrent #EndometrialCancer: A pre-specified subgroup analysis from Ph3 ENGOT-EN5/GOG-3055/SIENDO study 📅 When: 7/25 🔗 https://t.co/3RdAQrUEEO @OncoAlert #gyncsm @GynCancerMD (@ASCO)

Excited to share our Phase I trial data on the combo of Milademetan, LDAC +/- Ven in R/R TP53 WT AML & ND ts-AML. We performed CyTOF & sc-proteomic analysis to study mechanisms of resistance to therapy. @ CDiNardo @ Andreeff @ MMuftuoglu @DrHKantarjian https://t.co/Jbbrj0YX0Z (@jayastuMD)

This is a nodular/desmoplastic medulloblastoma. Typically driven by SHH pathway mutations and is TP53 wildtype. Nice work! (@CraigHorbinski)

Important note: trial only included patients with TP53-wild-type CLL. Unclear how much ibrutinib really adds from this study. #lymsm (@majorajay)

It is somehow contra-intuitive to have multiple gene rearrangements and low TMB... Is the patient living in a "nuclear risk" area ? RB1 orients toward NET. Not SCLC as p53 WT. Kind of LCNEC. Regardless of pathology will treat with CT-IO and try to introduce PARP inh... (@JulienMazieres)

Is selinexor uniquely effective for del17p? We highlight how Karyopharm markets selinexor as being more effective for p53 "wildtype" in other cancers, and being more effective for p53 mutant/17p deleted myeloma. How can the same drug with same mechanism of action do that?! (@ManniMD1)

Benefit of Vyxeos in secondary AML comes almost entirely from subgroup w DNTM3A and TET2 mutations. Didn’t help at all for TP53mut. Ven/aza inferior in TP53 Mut vs wt although good CR rate in poor risk cytogenetics w p53wt. Data from @ColemanLindsley & @DanPollyea #ASH22 (@Jmarksloan)

🔥Molecular classification of appendiceal adenocarcinoma @JCO_ASCO https://t.co/fitcM2MZqf ✅164 pts MSK-IMPACT 👉25% druggable🎯GA ✅3 subtypes: 👉mRAS,GNAS WT, TP53 WT: clinically indolent 👉mGNAS: CTx resistant 👉mTP53: aggressive, highly aneuploid @myESMO @OncoAlert ()

Treatment sequencing: cumulative costs are lower when starting with time-limited venetoclax + obintuzumab in first-line CLL (compared to starting with oral continuous therapy), in both TP53 WT & mut disease. Important implications for health systems. #ASH22 #lymsm #costsofcare (@majorajay)

.@RutgersCancer / @RWJBarnabas Dr. Andrew Evens (@DrAEvens) & colleagues present “Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma” at #ASH22. @ASH_hematology @RWJMS https://t.co/jw096NPban (@RutgersCancer)

Interesting study in @JCO_ASCO from @MSKCancerCenter (@ldiaz1971 & @AndreaCercek) Molecular Classification of Appendiceal Adenocarcinoma https://t.co/HLMB5Yb5SS Three genetic subtypes that dictate clinical behavior: KRAS mutant / GNAS, p53 WT GNAS mutant P53 mutant (aggressive+) (@Aiims1742)

Day 6: impact of cytogenetics and TP53 on outcomes in AML treated with Aza-Ven -poor-risk cytogenetics w/ TP53wt had improved outcomes w/ Aza-Ven compared to Aza -TP53m AML had similarly poor OS with Aza-Ven & Aza https://t.co/TDGYupBk9p (@Anand_88_Patel)

Presence of Concurrent TP53 Mutations Is Necessary to Predict Poor Outcomes within the SMAD4 Mutated Subgroup of Me… https://t.co/zNsB7JkyIW In this work, we show that the concurrent p53MT/SMAD4MT MCRC tumors are associated with poor outcome while p53WT/SMAD4MT are not. (@mgfakih)

3/6 A Phase I/II Study Of Milademetan (MDM2i) In Combination With LDAC +/- VEN In AML R/R AML + WT TP53; N=16 ORR= 2/16 (13%); Blast redu. 5/16 (31%) TP53 mut post Rx=1/16 (6%) @ DiNardo @HusseinAbbas01 @Daver_Leukemia @doctorpemm @sanamloghavi @AML_Hub https://t.co/opb47Fpah7 (@jayastuMD)

MDM2i have been primarily studied in TP53 wild type AML (the drugs work by inhibiting the MDM2-p53 axis and increasing/stabilising p53 levels and activity). Thus limited role in TP53 mutated disease. However, even in WT TP53 setting, responses have been modest (MIRROS trial). (@jayastuMD)

Selinexor works better for TP53 wildtype endometrial cancer and also works better for TP53 mutated myeloma. Amazing! Or we just got fooled by pharma. (@AaronGoodman33)

Why mutations matter for #colorectalcancer #liver #metastasis? 50% 5y survival after #hepatectomy+resection of extrahepatic disease if RAS/TP53 wildtype vs 25% if mutant @hlillemoe @SSATNews @MDAndersonNews @AnnalsofSurgery #oncsurgery @sgswisher @mkatzmd https://t.co/bYmIBm9kTX (@VautheyMD)

Hey lymphoma peers. 90+ yo, surprisingly fit. Mild lymphadenopathy. No B-symptoms. MCL, Ki-67 20%, TP53 wild-type. What do you recommend? Any thoughts? @tobyeyre82 @AaronGoodman33 @graham74GC @ChrisRRenner @michaelwangmd (@ThiloZander)